• Bilal H Naqvi MD

  • Physician - Hematology/Oncology


    • Oncology
    • 2200 Craig Road ECO Eau Claire, WI 54701

Education


2002:
Fellowship, Hematology/Oncology, University of Connecticut - Health Center, Farmington, CT
1999:
Residency, Internal Medicine, University of Connecticut - Health Center, Farmington, CT
1997:
Internship, Internal Medicine, University of Connecticut - Health Center, Farmington, CT
1994:
MD, University of the Punjab - King Edward Medical College, Lahore, Punjab, Pakistan
1987:
Cadet College Hasan Abdal, Pakistan

Work Experience


2004 to Present:
Oncologist / Hematologist, Physician, Marshfield Clinic Inc. - Marshfield Clinic Cancer Center - Eau Claire, Eau Claire, WI
2004 to Present:
Attending Physician, Marshfield Clinic Inc. - Chippewa Falls Center, Chippewa Falls, WI
2002 to 2004:
Consultant Oncologist, Shaukat Khanum Cancer Hospital & Research Center, Lahore, Pakistan
1994 to 1995:
Internal Medicine, Mayo Hospital, Lahore, Pakistan
1994 to 1994:
General Surgery, Mayo Hospital, Lahore, Pakistan

Board Certifications


2004 to 2018:
American Board of Internal Medicine - Hematology (2004), Recertified
1999 to 2021:
American Board of Internal Medicine (1999), Recertified
2003 to 2023:
American Board of Internal Medicine - Medical Oncology (2003), Recertified

Professional Societies


American Society of Clinical Oncology
American Society of Hematology

Select Publications


  • Bilgrami S, Edwards RL, Bona RD, Kazierad D, Furlong F, Fox JG,...Tutschka PJ. (2000). A pilot study of busulfan, cyclophosphamide and etoposide followed by autologous transplantation for acute myeloid leukemia in remission. Acta Haematol. 104(2-3):144-147.
    PubMed ID: 11154994
  • Tutschka PJ, Bilgrami SA, Feingold JM, Edwards RL, Bona RD, Naqvi BH, Clive J. (2001 August). Cytoreduction and stem cell mobilization with a regimen of paclitaxel, etoposide and cyclophosphamide followed by autologous transplantation using a preparative regimen of busulfan, etoposide and cyclophosphamide for patients with advanced lymphoma. Acta Haematol. 105(4):222-232.
  • Bilgrami S, Bona RD, Edwards RL, Li Z, Naqvi BH, Shaikh S,...Tutschka PJ. (2001 July). Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma. Bone Marrow Transplant. 28(2):137-143.
    PubMed ID: 11509931
  • Tutschka PJ, Bilgrami S, Feingold JM, Edwards RL, Bona RD, Naqvi BH, Clive J. (2001). Cytoreduction and stem cell mobilization with a non-ablative high intensity chemotherapy regimen of paclitaxel, etoposide, and cyclophosphamide (D-TEC) followed by autologous transplantation using an ablative high intensity preparative regimen of busulfan, etoposide and cyclophosphamide (BuCET) for patients with advance lymphoma Acta Hemato. 105(4):222-232.
    PubMed ID: 11528096
  • Naqvi BH, Dorsky D, Ali SA, Feingold JM, Edwards RL, Bona RD,...Bilgrami S. (2001 August). Efficacy of clarithromycin in preventing viridans streptococcal bacteremia following autologous stem cell transplantation Infection. 29(4):201-204.
    PubMed ID: 11545480
  • Bilgrami S, Metersky ML, McNally D, Naqvi BH, Kapur D, Raible D,...Tutschka PJ. (2001 February). Idiopathic pneumonia syndrome following myeloablative chemotherapy and autologous transplantation. Ann Pharmacother. 35(2):196-201.
    PubMed ID: 11215840
  • Badar F, Moid I, Waheed F, Zaidi A, Naqvi BH, Yunus S. (2005 January). Variables associated with recurrence in breast cancer patients-the Shaukat Khanum Memorial experience. Asian Pac J Cancer Prev. 6(1):54-57.
    PubMed ID: 15780033
  • Badar F, Moid I, Waheed F, Zaidi A, Naqvi BH, Yunus S. (2005 June). Survival analyses of breast cancer patients--the Shaukat Khanum Memorial experience. Asian Pac J Cancer Prev. 6(2):135-138.
    PubMed ID: 16101321
  • Rashid MU, Zaidi A, Torres D, Sultan F, Brenner A, Naqvi BH,...Hamann U. (2006 December). Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. Int J Cancer. 119(12):2832-2839.
    PubMed ID: 16998791